PLGA nanoparticles as an efficient carrier in <i>Toxoplasma</i> GAP45: a more effective vaccine against acute toxoplasmosis than traditional ones.

ABSTRACT:

Introduction

Toxoplasma gondii (T. gondii), as a strict intracellular parasite, can infect nearly all mammals, including humans, posing significant threats to public health. Toxoplasmosis in animals also leads to substantial economic losses in animal husbandry. Currently, no effective treatments are available for toxoplasmosis, creating an urgent need for safe and efficient therapeutics.

Methods

In this study, we constructed a subunit vaccine using T. gondii glidesome-associated protein 45 (TgGAP45). To enhance immunogenicity, poly (lactic-co-glycolic acid) (PLGA) nanoparticles were employed as delivery carriers to prepare TgGAP45-PLGA nanospheres. For comparison, two oil adjuvants, Montanide™ ISA 660 VG and Montanide™ ISA 206 VG, were used to formulate

SUBMITTER: Zhou P 

PROVIDER: S-EPMC12229859 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature